Sponsor: Memorial Sloan-Kettering Cancer Center
Sponsor Study ID: 22-090
Study Title: A Phase II, Multicenter, Single-Arm Clinical Trial of Definitive Radiotherapy And CeMiPlimAb-Rwlc ImmunoTherapy for Locally Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: RAMPART
CTO #: 103905
NCT Number: NCT05574101
Phase: II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Melanoma, Skin, Other Skin
Study Objectives: Disease Free Survival [Time Frame: 18 months] The primary endpoint for this study is disease free survival at 18 months (week 78 +/- 3 weeks) after starting cemiplimab.